Cargando…
O6.8. GLUTAMATERGIC DYSFUCTION AND TREATMENT RESPONSE IN MINIMALLY TREATED AND CHRONIC SCHIZOPHRENIA PATIENTS
BACKGROUND: Glutamatergic dysfunction as a result of NMDA receptor hypofunction has been implicated in antipsychotic treatment-resistant schizophrenia, however its nature in very early stages and chronic stages of the disease is still unknown. Data on glutamate and treatment response are currently l...
Autores principales: | Mouchlianitis, Elias, Vanes, Lucy, Barry, Erica, Patel, Krisna, Wong, Katie, Porfy, Lilla, Shergill, Sukhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887993/ http://dx.doi.org/10.1093/schbul/sby015.229 |
Ejemplares similares
-
Cognitive correlates of abnormal myelination in psychosis
por: Vanes, Lucy D., et al.
Publicado: (2019) -
Neuroimaging glutamatergic mechanisms differentiating antipsychotic treatment-response
por: Mouchlianitis, Elias D., et al.
Publicado: (2023) -
Neural correlates of positive and negative symptoms through the illness course: an fMRI study in early psychosis and chronic schizophrenia
por: Vanes, Lucy D., et al.
Publicado: (2019) -
S148. DIFFERENTIAL NEURAL REWARD MECHANISMS IN TREATMENT RESPONSIVE AND TREATMENT RESISTANT SCHIZOPHRENIA
por: Vanes, Lucy, et al.
Publicado: (2018) -
Author Correction: Neuroimaging glutamatergic mechanisms differentiating antipsychotic treatment-response
por: Mouchlianitis, Elias D., et al.
Publicado: (2023)